Abstract
Mitoxantrone at a dose of 12 mg/m2 i.v. q 3 weeks failed to produce a response in 28 adequately treated patients with measurable advanced bladder cancer. The side-effects observed in this group of patients with a good performance status were generally mild. On the basis of this negative result the use of mitoxantrone in this disease cannot be recommended.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Anthraquinones / adverse effects
-
Anthraquinones / therapeutic use*
-
Antineoplastic Agents / therapeutic use*
-
Drug Evaluation
-
Female
-
Humans
-
Leukopenia / chemically induced
-
Male
-
Middle Aged
-
Mitoxantrone
-
Urinary Bladder Neoplasms / drug therapy*
Substances
-
Anthraquinones
-
Antineoplastic Agents
-
Mitoxantrone